Evolus, Inc. (EOLS)
Stock Price:
$3.44 USD
-0.09 (-2.55%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $3.43 -0.01 (-0.29%) Oct 22, 4:59 PM
Key Info
| Market Cap |
116.09M |
| Revenue (ttm) |
50.92M |
| Net Income (ttm) |
-82.35M |
| Shares Out |
33.75M |
| EPS (ttm) |
-2.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$3.44 |
| Previous Close |
$3.53 |
| Change ($) |
-0.09 |
| Change (%) |
-2.55% |
| Day's Open |
3.55 |
| Day's Range |
3.40 - 3.59 |
| Day's Volume |
399,730 |
| 52-Week Range |
3.00 - 17.68 |
More Stats
| Market Cap |
116.09M |
| Enterprise Value |
128.71M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.75M |
| Float |
21.95M |
| EPS (basic) |
-2.63 |
| EPS (diluted) |
-2.62 |
| FCF / Share |
-2.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.43M |
| Short Ratio |
7.15 |
| Short % of Float |
15.62% |
| Beta |
2.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.28 |
| PB Ratio |
2.73 |
| Revenue |
50.92M |
| Operating Income |
-73.96M |
| Net Income |
-82.35M |
| Free Cash Flow |
-86.84M |
| Net Cash |
-12.62M |
| Net Cash / Share |
-0.37 |
| Gross Margin |
52.85% |
| Operating Margin |
-145.26% |
| Profit Margin |
-161.70% |
| FCF Margin |
-170.55% |
| ROA |
-25.32% |
| ROE |
-194.26% |
| ROIC |
-49.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
5 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$10.62*
(208.72% upside)
Low
4.00
Current: $3.44
High
35.00
Target: 10.62
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 34.93 | - | - | - | - |
| Gross Profit | 26.91 | - | - | - | - |
| Operating Income | -98.95 | -46.14 | -11.73 | -19.97 | -30.98 |
| Net Income | -90.03 | -46.87 | -4.48 | -20.07 | -31.11 |
| Shares Outstanding | 28.24 | 24.40 | 16.53 | 16.53 | 16.53 |
| Earnings Per Share | -3.19 | -1.92 | -0.27 | -1.21 | -1.88 |
| Operating Cash Flow | -93.38 | -25.67 | -13.22 | -13.27 | -36.38 |
| Capital Expenditures | -4.57 | -0.01 | - | - | - |
| Free Cash Flow | -97.95 | -25.68 | -13.22 | -13.27 | -36.38 |
| Cash & Equivalents | 130 | 93.16 | - | 0.19 | 4.00 |
| Total Debt | 96.55 | 16.90 | 211 | 59.76 | 46.17 |
| Net Cash / Debt | 33.26 | 76.26 | -211 | -59.57 | -42.17 |
| Assets | 240 | 172 | 152 | 77.50 | 81.30 |
| Liabilities | 161 | 87.46 | 228 | 84.60 | 69.30 |
| Book Value | 79.46 | 84.38 | -75.54 | -7.11 | 12.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Evolus, Inc. |
| Country |
United States |
| Employees |
127 |
| CEO |
David Moatazedi |
Stock Information
| Ticker Symbol |
EOLS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: EOLS |
| IPO Date |
February 8, 2018 |
Description
Evolus, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.